Zeldinac-MR Tablet is a combination medication containing Chlorzoxazone 250 mg, Diclofenac 50 mg, and Paracetamol 325 mg, formulated for the management of musculoskeletal pain and inflammation. Chlorzoxazone acts as a centrally-acting muscle relaxant, alleviating muscle spasms and discomfort, while Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), provides potent anti-inflammatory and analgesic effects by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis. Paracetamol contributes additional analgesic and antipyretic properties, enhancing overall pain relief. This synergistic combination is indicated for conditions such as acute musculoskeletal injuries, strains, sprains, and other painful musculoskeletal disorders where inflammation and muscle spasm coexist. Zeldinac-MR is typically administered orally, with dosing tailored to the severity of symptoms and patient response. Caution is advised in patients with hepatic, renal, or cardiovascular impairment, and it should be used under medical supervision to minimize potential adverse effects including gastrointestinal irritation, hepatotoxicity, or hypersensitivity reactions. The medication should be avoided in individuals with known hypersensitivity to any of its components. Regular monitoring and adherence to prescribed dosage are essential to ensure safety and efficacy during treatment.